Drug news
Endo International acquires world rights to Sumavel Dose Pro for Migraine from Zogenix Inc.
Endo International plc has announced that affiliates of the company have completed the acquisition of worldwide rights to Sumavel DosePro (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo's current cash on hand.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins